Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / OBSV - ObsEva's nolasiban flunks late-stage study; shares down 24% premarket


OBSV - ObsEva's nolasiban flunks late-stage study; shares down 24% premarket

  • ObsEva SA (NASDAQ:OBSV) is down 24% premarket on light volume in reaction to its announcement that lead drug nolasiban failed to achieve the primary endpoint in a Phase 3 clinical trial, IMPLANT4, aimed at demonstrating that a single oral dose increased the pregnancy rate in women undergoing in vitro fertilization (IVF). The company has decided to terminate development for IVF and is exploring "repositioning" the oxytocin receptor antagonist.
  • More news on: ObsEva SA, Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com

Menu

OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...